MyFinsight
Home
Blog
About
Sale and maturities
of available for...
$45,140K
(-56.83%↓ Y/Y)
Net cash provided by
(used in) investing...
$13,681K
(213.19%↑ Y/Y)
Effect of exchange
rates on cash and cash...
$1K
(103.03%↑ Y/Y)
Canceled cashflow
$31,459K
Net increase
(decrease) in cash and cash...
-$681K
(88.67%↑ Y/Y)
Canceled cashflow
$13,682K
Proceeds from sale of
common stock and...
$620K
(-96.22%↓ Y/Y)
Depreciation and
amortization expense
$2,296K
(-52.31%↓ Y/Y)
Stock-based compensation
$970K
(-63.63%↓ Y/Y)
Other long-term
assets
-$575K
Change in fair value of
convertible debentures
-$114K
(-102.17%↓ Y/Y)
Cost of leased
equipment sold to customer
$96K
(-55.35%↓ Y/Y)
Inventory
-$77K
(95.80%↑ Y/Y)
Amortization of financing
lease right-of-use...
$51K
(-50.00%↓ Y/Y)
Purchase of available for
sale securities
$31,459K
(-73.03%↓ Y/Y)
Net cash provided by
(used in) financing...
-$9,693K
(-178.42%↓ Y/Y)
Canceled cashflow
$620K
Net cash used in
operating activities
-$4,670K
(25.29%↑ Y/Y)
Canceled cashflow
$4,179K
Payments on convertible
debentures
$10,266K
(242.20%↑ Y/Y)
Offering expenses on sale
of common stock and...
$26K
(-97.46%↓ Y/Y)
Principal payments of
financing lease liability
$21K
(-38.24%↓ Y/Y)
Net loss
-$7,423K
(25.46%↑ Y/Y)
Accrued expenses,
contract liabilities,...
-$550K
(69.83%↑ Y/Y)
Accounts payable
-$500K
(30.46%↑ Y/Y)
Accounts receivable
$233K
(118.54%↑ Y/Y)
Accretion of interest on
securities
$109K
(-77.80%↓ Y/Y)
Prepaid expenses and
other current assets
$26K
(157.78%↑ Y/Y)
Non-cash lease expense
-$8K
(-101.37%↓ Y/Y)
Back
Back
Cash Flow
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)
source: myfinsight.com